• Assure Holdings (IOM) has announced its expansion into telemedicine by launching professional neurology services for its IONM services
  • The company has already performed its first telehealth case
  • Assure recently made its first two telehealth hires and is actively recruiting to fill additional positions
  • Assure Holdings works with neurosurgeons and orthopedic spine surgeons to provide services that support intraoperative neuromonitoring activities during invasive surgeries
  • Assure Holdings (IOM) opened trading at C$1.80 per share

Assure Holdings (IOM) has announced its expansion into telemedicine by launching professional neurology services for its IONM services.

The company has already performed its first case using the new telehealth services.

The transition will be straightforward as Assure replaces the third-party vendor they are currently using with professional services furnished through its subsidiary.  

John A. Farlinger, Assure’s executive chairman and CEO, commented,

“The company’s expansion into telehealth represents an important milestone in establishing Assure as the standard of care in the intraoperative neuromonitoring (IONM) industry and a leading provider in the United States.

Further, we intend to market this offering to doctors and medical groups that need telehealth neurology services associated with epilepsy, electroencephalogram (EEG) and sleep disorders, among other services,” he said.

Assure recently made its first two hires relating to the company’s telehealth professional neurology services.

The company is actively recruiting to fill additional positions and expects to gradually add more staff over the course of 2021 and beyond.

Assure Holdings is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries.

Assure Holdings (IOM) opened trading at C$1.80 per share.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.